This system specifically reduces m6A modification on phospholipid phosphatase 3 (PLPP3) mRNA establishing a mechanistic foundation for developing siRNA-based therapeutic strategies against m6A-related neurological disorders. The gene discussed is PLPP3; the disease is nervous system disorder.